Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. - Wikidata - wikimedia - TriplyDB

Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.

Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.

http://www.wikidata.org/entity/Q33914222

about

Intrabody and Parkinson's disease The P42 peptide and Peptide-based therapies for Huntington's disease Mechanisms of RNA-induced toxicity in CAG repeat disorders Intrabodies as neuroprotective therapeutics Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment.Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm.Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.Probing the metabolic aberrations underlying mutant huntingtin toxicity in yeast and assessing their degree of preservation in humans and mice.Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice.Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease.Neurodegenerative models in Drosophila: polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis.Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease.Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.Grape-seed polyphenolic extract improves the eye phenotype in a Drosophila model of tauopathy.Selective blockade of trypanosomatid protein synthesis by a recombinant antibody anti-Trypanosoma cruzi P2β protein Differential nuclear localization of complexes may underlie in vivo intrabody efficacy in Huntington's disease.Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.POTENTIAL APPLICATION OF GRAPE DERIVED POLYPHENOLS IN HUNTINGTON'S DISEASE Palmitoyl-protein thioesterase 1 deficiency in Drosophila melanogaster causes accumulation of abnormal storage material and reduced life span A huntingtin peptide inhibits polyQ-huntingtin associated defects Selection and characterization of llama single domain antibodies against N-terminal huntingtin Effects on murine behavior and lifespan of selectively decreasing expression of mutant huntingtin allele by supt4h knockdown Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration.The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases.Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.The emerging role of the first 17 amino acids of huntingtin in Huntington's disease Anti-Aβ single-chain variable fragment antibodies exert synergistic neuroprotective activities in Drosophila models of Alzheimer's disease Transcriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington's disease Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin Protein-based tumor molecular imaging probes.Immunological features of alpha-synuclein in Parkinson's disease.Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity.

P2860

Q24653530-C9E942C7-800A-4693-8525-DA24687D5598 Q26764930-873357A3-57B5-45AD-A677-F5BFC056C7BF Q26860030-6C1C02F8-1279-4EBE-A8A4-4F138D8AE73D Q27003896-7C86ECB1-D4C4-4474-A96C-BF47C9373AF6 Q28740551-BF993046-C4AB-4125-9693-BF39B17ED7D5 Q30490726-BF6DE1C4-D8E3-42A2-A421-A5FC396BBF95 Q30493159-E1D0337A-F063-4C37-A0E5-DA3D0CAFC5C5 Q30980477-B70F64E5-0014-4520-BC31-B1F3CC5199DB Q33280345-A0884900-0BC4-4150-BE54-9D486F8F664A Q33317678-FD10432C-DBB9-433E-B3C9-38CF2B1EC567 Q33459255-8A1008C1-E68C-445A-AFB2-671A5F157F45 Q33571914-D6C418BC-80C9-4AF1-B93B-CF262053B972 Q33594383-8C93ACF5-4213-4ED8-9F24-07606EE794D5 Q34077018-EADB9C31-3B4E-4240-821F-C353DA71A153 Q34079770-05D6B781-D8FC-42F8-AD1D-97CD47289310 Q34109060-56607642-05D8-433B-BF95-D019F01D2679 Q34117333-BBCB64AB-4473-4A82-953A-1C689B05CAF1 Q34143466-48315E42-6651-4B60-A1B7-1513DBE3C0EE Q34263241-8B8C9898-5EA7-4AC6-88EC-08B11DF33A65 Q34313192-D4AD260A-03AA-4157-A002-425FA3DEAE3D Q34373713-8ABF6C82-2C24-4A03-A5D6-DC2B50E8CFFA Q34576042-FDAEE6D8-68FE-4F09-93D1-564202FAC2D3 Q34588532-B0FED465-BB81-4791-963C-253FA3BF45CA Q34828144-A84D085F-F892-4156-8608-5263B952092F Q35123206-887A1CD8-E211-40E0-8346-95157EFD09DD Q35168414-F0F96892-61A5-4E7A-9208-3713303ED23F Q35244160-4C93761E-74E0-43C5-B567-8787911204D9 Q35542169-47639739-AD48-49B2-8B18-EE7DD9F0F991 Q35708355-0AB7EBFE-5382-4D74-8F90-0247443886D9 Q35748307-EB278268-A078-48C2-8CE3-86BD40E5258F Q35992493-93FD5291-8B0B-47E4-9D9D-5AC49B3FEE7D Q36110838-C94DA2BF-6C66-416F-9FA1-C68C3A6EB58B Q36142379-748A9EBE-B0E0-44F7-9EBC-C3D5F3672732 Q36142398-1370FE09-BC05-45F8-BE63-4AB0349C1A60 Q36677547-D367D643-27A5-4ED7-BE59-542D5F847ADC Q36742911-C18C6F36-FE6A-459A-8197-19687E031CBA Q37232067-6826A037-CD58-4F16-89D7-FB38546C413B Q37280507-62588501-5083-4BC8-8645-CA5B101967B2 Q37397677-FB4285B6-E9F2-4AEB-A11A-2E9DCD8A4EC2 Q37447680-EE44FFE5-38B1-40AD-AAC4-409A858077B4

P2860

Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.

http://www.wikidata.org/entity/Q33914222

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Suppression of Huntington's di ...... an single-chain Fv antibodies.

@ast

Suppression of Huntington's di ...... an single-chain Fv antibodies.

@en

type

label

Suppression of Huntington's di ...... an single-chain Fv antibodies.

@ast

Suppression of Huntington's di ...... an single-chain Fv antibodies.

@en

prefLabel

Suppression of Huntington's di ...... an single-chain Fv antibodies.

@ast

Suppression of Huntington's di ...... an single-chain Fv antibodies.

@en

P1433

Q33914222-E8A866A4-A1DD-49DC-9A6F-D6D888EAB995

P1476

Q33914222-CEA704AC-A846-4F01-822A-272BE7E949D6

P2093

Q33914222-036654D4-5E31-49EA-83B1-975AA3DAA060

Q33914222-19D4A14D-19E7-4A7C-8EF9-3C9674BFA421

Q33914222-1FD5B676-FEC4-463A-8608-1AD493DD0084

Q33914222-2A27598F-560E-4E25-8762-A51E1DD3A3E9

Q33914222-912343AF-C334-449E-969E-36C1A3FBFFE6

Q33914222-F0E9F4A6-4925-4AE2-9B58-202B92919A68

P2860

Q33914222-04786991-E2EC-4DBF-A3F2-2453D7895532

Q33914222-0A04085A-2D13-42AA-97FC-5C6B6C37EB3F

Q33914222-0B54D047-D7F9-4D01-8B79-5C3F0144F5DC

Q33914222-10CD0B78-39D6-4C2C-B64B-53E085CFAA19

Q33914222-1467035B-0727-4F9F-AC15-B12FCD77BBC4

Q33914222-168B5916-4681-4E62-B649-480A8D81FA95

Q33914222-1BBEE834-326C-47AA-A461-3429504B1C2A

Q33914222-21961998-4E12-4373-B773-C26E23DF7188

Q33914222-2997BBDF-1191-48A8-AF86-98EC37F35A79

Q33914222-2FA3EA00-0548-4DD5-AB19-BF27B045C485

P304

Q33914222-D42BBDD3-DF96-45B3-A93C-F09F50B9E689

P31

Q33914222-D458AF81-D8CC-42FA-9024-E9408B4C5814

P356

Q33914222-9E31A810-798E-4165-84F2-2A430563850A

P407

Q33914222-9A5709F5-A3E0-41BA-802F-54AC9737E6E8

P433

Q33914222-7E20604E-A98D-4BB7-9206-EBBCE0B77FC5

P478

Q33914222-A6D9DBD4-1FCF-4FA2-982C-954C1FC3D0F5

P50

Q33914222-5883D91A-406A-4708-97B3-A06F5C14F234

P577

Q33914222-5B58B8B0-5657-43B2-9D31-2BC60C257669

P5875

Q33914222-5DDC3BC3-9C00-4891-A707-6BD43EC5118F

P698

Q33914222-9E651774-5CB2-464F-9FD4-E0248DE4C310

P921

Q33914222-516A43B1-71B0-4054-BF2C-2B1DE20FE0AD

Q33914222-60509A54-7F1F-4FF5-8D06-E7D689606875

Q33914222-D26706E9-52D9-43AE-A242-1A035DFAB546

P932

Q33914222-2C7DA30E-336D-4FDD-B6D0-57FAA1D3D3E7

P356

PNAS.0505321102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Suppression of Huntington's di ...... man single-chain Fv antibodies

@en

P2093

Anne Messer

http://www.w3.org/2001/XMLSchema#string

J Lawrence Marsh

http://www.w3.org/2001/XMLSchema#string

Jack M Webster

http://www.w3.org/2001/XMLSchema#string

James S Huston

http://www.w3.org/2001/XMLSchema#string

Leslie M Thompson

http://www.w3.org/2001/XMLSchema#string

Todd W Miller

http://www.w3.org/2001/XMLSchema#string

P2860

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

Targeted gene expression as a means of altering cell fates and generating dominant phenotypes

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

Can flies help humans treat neurodegenerative diseases?

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

Protein aggregation and neurodegenerative disease

Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

P304

11563-11568

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0505321102

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

William J Wolfgang

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7685697

http://www.w3.org/2001/XMLSchema#string

P698

16061794

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

1183604

http://www.w3.org/2001/XMLSchema#string